MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • 2024 International Congress

    Eye Blink Rate and Putamen DaTScan Covariation in Parkinson’s Disease

    Q. Salardaine, V. Vasudevan, N. Villain, E. Biondetti, S. Lehéricy, M. Vidailhet, P. Pouget (Paris, France)

    Objective: To examine the relationship between blink rate and DaTScan in Parkinson’s disease. Background: Spontaneous eye-blink rate (BR) is blinking without external triggers. Parkinson's disease…
  • 2024 International Congress

    Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis

    B. Wang, H. Wang, W. Luo (Hangzhou, China)

    Objective: The study aims to apply S-ICA to 18F-fluorodeoxyglucose (FDG) data in progressive supranuclear palsy (PSP) patients,  identifing PSP-specific independent metabolic covariate networks. We also…
  • 2024 International Congress

    Putaminal dopamine modulates movement motivation in Parkinson’s disease

    M. Banwinkler, V. Dzialas, L. Rigoux, H. Theis, A. Asendorf, K. Giehl, M. Tittgemeyer, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: To investigate the quantitative effect of dopamine depletion on the motivation of motor effort in Parkinson’s disease. Background: The relative inability to produce effortful…
  • 2024 International Congress

    Dopaminergic alterations in patients with Alzheimer’s disease

    M. Azharuddin, M. Sharma (New Delhi, India)

    Objective: The objective of this study was to conduct a meta-analysis to determine the pooled mean difference (MD) in dopaminergic measures between Alzheimer’s disease and…
  • 2024 International Congress

    Criteria Defining Chronic Pain Associated with Parkinson Disease

    S. Perez-Lloret, J. Hunger, J. Bally, G. Kägi, J. Möller, N. Hollenstein, R. Gonzenbach, F. Brugger, D. Ciampi-de-Andrade, V. Mylius (Buenos Aires, Argentina)

    Objective: To assess the factors defining the association of chronic pain (>3 months) with PD. Background: Non-motor symptoms can be often associated with Parkinson disease…
  • 2024 International Congress

    Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report

    M. Khommyatov, M. Samushiya, I. Smolentseva, S. Kryzhanovskiy (Moscow, Russian Federation)

    Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…
  • 2024 International Congress

    Characterizing Dopaminergic Correlates of Depression in Parkinson’s Disease: The PPMI Cohort

    C. Song, A. Basu, I. Bedoy, J. Li, J. Ruiz Tejeda, S. Nguyen, R. Rajmohan, N. Phielipp (Irvine, USA)

    Objective: We explored the association between cerebrospinal fluid (CSF) dopamine metabolites and transporter denervation in the development of depression in Parkinson Disease (PD). Background: Depression…
  • 2024 International Congress

    Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease

    C. Moreau, P. Odou, A. Demailly, G. Touzet, N. Reyns, J. Labreuche, A. Duhamel, C. Barthelemy, D. Lannoy, N. Carta, B. Palas, F. Marchand, B. Gouges, C. Leclerc, C. Potey, T. Ouk, K. Dujardin, S. Baigne, L. Carton, AS. Rolland, JC. Devedjian, V. Foutel, D. Deplanque, M. Fisichella, D. Devos (Lille, France)

    Objective: To assess the continuous intracerebroventricular (i.c.v.) of A-dopamine in patients with a telemetry-controlled intra-abdominal pump system connected to a subcutaneous catheter implanted through the…
  • 2024 International Congress

    The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.

    H. Geerts, S. Short (Princeton, USA)

    Objective: Understanding the biological link between alpha-synuclein biomarker changes and clinical outcome using computer simulation. Background: A number of disease modifying therapeutic interventions focused on…
  • 2024 International Congress

    Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach

    S. Jain (Gandhinagar, India)

    Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…
  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • #24752 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley